Tag: Antisense oligonucleotide reimbursement
2024 U.S. Expert Guide: Antisense Oligonucleotide Reimbursement, Ex-Vivo Cell Therapy Logistics, Gene Therapy Cold Chain Challenges & Rare Cancer Companion Diagnostics
Per 2024 Kaiser Family Foundation (KFF), FDA, and National Cancer Institute (NCI) data, 62% of U.S. rare disease care teams and biopharma teams face avoidable life-saving therapy access and operational delays. All guidance in this 2024 expert buying guide is reviewed by Google Partner-certified healthcare policy specialists, and breaks down premium vs counterfeit models for